




# Community pharmacies in HCV micro-elimination efforts in Scotland

Prof John Dillon

School of Medicine, University of Dundee, Ninewells Hospital and Medical School, NHS Tayside, Scotland.




# Scottish Health service and addiction services

- Free at point of delivery
- Addiction mainly Heroin and Benzo's historically
- Addictions services; Psychiatry and general practice
  - OST prescription
- OST dispensing- community pharmacy
  - Employed by health service on fee for service basis
  - Independent non-medical prescribers
  - Patient group directives



# Hepatitis C diagnosis and treatment pathways in Tayside



PWID defined as those who either (a) are currently injecting drugs, (b) have ever injected drugs and are currently on opioid substitute therapy, or (c) have ever injected drugs and are currently in prison

DBS: dried blood spot; OST: opioid substitution therapies; POC: point of care; PWID: people who inject drugs; IEPS injecting equipment provision sites



A research programme to model, evaluate and establish testing and treatment of hepatitis C infection in community pharmacy



"Standing Outside The Junkie Door – A Qualitative Study of the Views and Experiences of People Receiving OST from Community Pharmacy"

Themes Identified :-

# **Experiences of Care**

- Stigma and discrimination
- Confidentiality
- Changes that need to occur

**Knowledge and Experiences of Treatment** 

- Mechanics of care
- Burden of treatment

#### ASK THE PEOPLE we are trying to reach PREFERENCES FOR HCV TESTING: A DISCRETE CHOICE EXPERIMENT WITH OST USERS


Preference	Willing to Wait
Own rather than other	4.25 weeks
pharmacy	
Own pharmacy rather than GP	2.11 weeks
Own pharmacy rather than	0.08 weeks
drug worker	
Treated with respect	7.42 weeks

#### Dried blood spot testing in Tayside, Scotland

A quasi-experimental evaluation of DBST through community pharmacies in the Tayside region of Scotland


Pharmacy site	Number of	Number of tests	Number of
	eligible patients	taken	positive tests
		(% of eligible	
		patients)	
А	23	13 (57)	3
В	22	11 (50)	4
С	30	5 (17)	3
D	26	10 (38)	1
E	26	3 (12)	1
F	16	1 (6)	0
Totals	143	43 (30)	12

The OR for increased uptake of testing within the 6 pharmacies was 2.25 (95% CI 1.48 to 3.41, Z statistic = 3.81 p = <0.0001) in comparison to the other services



# HCV testing and treatment in 8 community pharmacies


**DOT-C: A pilot cluster randomised controlled trial** 



# HCV testing and treatment in 8 community pharmacies

**Outcomes for 40 reactive DBST** 

	Pharmacist-led (n=29)	Standard of care (n=11)
No assessment blood test	12 (42%)	5 (46%)
Genotype 3	7 (24%)	1 (9%)
Spontaneous clearance	6 (21%)	3 (27%)
Prison	1 (3%)	0
Deceased	0	1 (9%)
Treated	3 (10%)	1 (9%)
Available for treatment/treated	3/3 (100%)	1/1 (100%)



### **SuperDOT-C - Outcomes**

	Conventional Care Pathway	Pharmacist-Led Care Pathway	Odds Ratio	P Value
Primary Outcome				
SVR12	43	98	2.375	<0.0001
Secondary Outcomes				
Diagnosed & Agreed Treatment	137	219	1.696	<0.0001
Initiated Treatment	61	112	1.889	0.0015
Completed Treatment	58	108	1.928	0.0007
Diagnosed Population Cure Rate <sup>*</sup>				
	31%	45%		*SVR12/Number diagnosedx100
Notional Population Cure Rate <sup>+</sup>				
	8%	18%		+SVR12/Population at riskx100





#### Reaching People Receiving Opioid Agonist Therapy Attending Community Pharmacies with Hepatitis C Virus (Reach)

#### An international cluster randomised controlled trial

<u>Byrne C<sup>1,2</sup></u>, Radley A<sup>3</sup>, Inglis SK<sup>2</sup>, Beer L<sup>2</sup>, Palmer N<sup>4</sup>, Pham MD<sup>5,6</sup>, Allardice K<sup>6</sup>, Wang H<sup>7</sup>, Robinson E<sup>8</sup>, Hermansson M<sup>9</sup>, Semizarov D<sup>9</sup>, Healy B<sup>4</sup>, Doyle JS<sup>5,6</sup>, Dillon JF<sup>1,8</sup>

<sup>1</sup>Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, UK.

<sup>2</sup>Tayside Clinical Trials Unit, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, UK.


<sup>3</sup>Directorate of Public Health, NHS Tayside, Kings Cross Hospital, Dundee, UK.

<sup>4</sup>Department of Microbiology and Infectious Diseases Cardiff, Public Health Wales, UK.

<sup>5</sup>Department of Infectious Diseases, the Alfred and Monash University, Melbourne, Australia. <sup>6</sup>Disease Elimination Program, Burnet Institute, Melbourne, Australia.

<sup>7</sup>Division of Population Health and Genomics, School of Medicine, University of Dundee, UK.


<sup>8</sup> Department of Gastroenterology, NHS Tayside, Ninewells Hospital and Medical School, Dundee, UK.<sup>9</sup>AbbVie Ltd, AbbVie House, Vanwall Business Park, UK.




## Methods



- International (Scotland, Wales, Australia) cluster-randomised controlled trial of outreach point-of-care HCV RNA testing and DAA treatment versus conventional care for OAT clients at pharmacies.
- Pharmacies were randomised 1/1 to intervention or control arm.
- Pharmacists opportunistically discussed HCV with OAT clients and sign-posted to HCV testing.
- HCV testing in pharmacies in intervention sites, or community clinics (UK) and GPs (Aus) in control sites.
- DAAs arranged by nurses in UK under PGD, and clinician or GP in Aus.
- DAAs dispensed by pharmacists alongside OAT.







#### **EPITOPE**

### WS1 : A feasibility study on rapid major scale-up of DAAs among PW

- Rapid & major scale-up of DAAs among PWID (>500 over 2 years)
- Aim to reduce chronic HCV prevalence among PWID from 30% to <10%</li>
- Testing (by services) & treatment (by specialist nurses & pharmacists) in multiple community settings



# EPITOPE HCV treatment scale up for PWID



1. Proportions of treatments, 2. completion, 3. lost to follow-up, and 4. cure

\*Percentages are proportions of the LTFU group (n=70), not treated cases.

†SVR for treatment completers who received a test (n=560).

How close to elimination are we in Tayside? HCV chronic prevalence 0.5% of population= 1,975 90% of chronic prevalence = 1,776

	Infections	People
Total ever diagnosed	4,535	4,322
PCR negative	1,056	1043
Non resident	708	703
Died	698	698
Total alive and living in Tayside	2,031	1,878

Total treated (treated and SVR with Interferon or	1,969	1,812
completed course of DAA)		

#### Acknowledgements

The Team- Nik Rae, Morgan Evans, Jan Tait, Brian Stephens, Emma Robinson, Maya Prakash, Dianne Knight, Farsana Ahmed, Andrew Radley, Linda Johnston, Shirley Cleary, Christian Sharkey, Sarah Inglis, Lewis Beer, Chris Byrne, Amy Malaguti, Steve McSwiggan, James Flood, Donna Thain, Ann Eriksen, Sarah Donaldson



External Collaborators-Matt Hickman, Peter Vickerman, Natasha Martin, Jeff Lazarus, Margaret Hellard, Joe Doyle, Sharon Hutchinson, David Goldberg